Licensing status

Publication and contact information

Drug platforms

Induced pluripotent stem (iPS) cell-derived immortalized megakaryocyte progenitor cell lines as a self-renewing source for human platelets

In vitro and mouse studies suggest iPS cell-derived platelets could be used for clinical applications. Stable, immortalized megakaryocyte progenitor cell lines were generated from iPS cells by overexpression of BMI1 polycomb ring finger oncogene (BMI1), Bcl-xL and c-Myc (MYC), and the cells produced platelets when transgene expression was turned off. In vitro, aggregation of immortalized megakaryocyte progenitor cell line-derived platelets was lower than that of fresh human platelets but comparable to that of other iPS cell-derived platelets or pooled human endogenous platelets. In a mouse model of thrombocytopenia, the platelets adhered to laser-exposed vessel walls and contributed to thrombus formation. Next steps could include optimizing megakaryocyte maturation, efficiency of platelet release into liquid culture systems and platelet yield per megakaryocyte.

SciBX 7(9); doi:10.1038/scibx.2014.270
Published online March 6, 2014

Patent application filed; in negotiations for licensing to an undisclosed company; unavailable for licensing

Nakamura, S. et al. Cell Stem Cell; published online Feb. 13, 2014;
Contact: Koji Eto, Kyoto University, Kyoto, Japan